Across TCGA cell cohorts, CLCNKA mutation is significantly associated with the drug of many other genes, with 31 significant associations in total. LARGE_INTESTINE shows the largest number of these associations.

The most reproducible CLCNKA-associated genes across cancer lineages are Niraparib, Luminespib, and GSK2801. Each is linked with CLCNKA in more than 1 cancer types. Because this analysis shows association rather than direction, both CLCNKA-to-partner and partner-to-CLCNKA results are reported.

Each partner links to its own Q-omics profile.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (CLCNKA→partner) and Y-score (partner→CLCNKA) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LARGE_INTESTINE	Niraparib →	+0.486	+2.646	.005	.047	3	1
LARGE_INTESTINE	Luminespib →	+0.699	+2.646	.021	.047	3	1
LARGE_INTESTINE	GSK2801 →	+0.314	+2.649	.049	.046	3	1
LARGE_INTESTINE	RVX-208 →	+0.439	+2.646	.003	.047	3	1
LARGE_INTESTINE	LMP744 →	+0.795	+2.710	.018	.027	3	1
LARGE_INTESTINE	Zibotentan →	+0.235	+2.652	.020	.045	3	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 31 associations by consensus.

Exploration

CLCNKA survival (RNA) · tumor vs normal (RNA) · all CLCNKA data types